✦ LIBER ✦

A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings

✍ Scribed by Stéphane Oudard; Olivier Rixe; Benoit Beuselinck; Claude Linassier; Eugeniu Banu; Jean-Pascal Machiels; Marion Baudard; François Ringeisen; Thierry Velu; Marie-Aude Lefrere-Belda; Jean-Marc Limacher; W. H. Fridman; Michel Azizi; Bruce Acres; Eric Tartour

Publisher: Springer-Verlag
Year: 2010
Tongue: English
Weight: 411 KB
Volume: 60
Category: Article
ISSN: 0340-7004
DOI: 10.1007/s00262-010-0935-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of lenalidomide in patien

Phase II study of lenalidomide in patients with metastatic renal cell carcinoma

✍ Toni K. Choueiri; Robert Dreicer; Brian I. Rini; Paul Elson; Jorge A. Garcia; Sn 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 438 KB 👁 1 views

Phase I/II study of thalidomide in combi

Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma

✍ Robert J. Amato; Margaret Morgan; Anish Rawat 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

A phase 2 study with a daily regimen of

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

✍ Robert J. Amato; Jaroslaw Jac; Sarah Giessinger; Somyata Saxena; James P. Willis 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 2 views

Granulocyte-macrophage–colony stimulatin

Granulocyte-macrophage–colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma : Results of two Phase II clinical trials

✍ Christopher W. Ryan; Nicholas J. Vogelzang; Mary C. Dumas; Timothy Kuzel; Walter 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

The aim of this study was to determine the response rates and toxicity of two regimens containing granulocyte-macrophage-colony stimulating factor (GM-CSF) in combination with interleukin-2 (IL-2) in the treatment of patients with metastatic renal cell carcinoma. ## METHODS. Therapy given in the f

A clinical phase I/II trial with the mon

A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients

✍ M. Siebels; K. Rohrmann; R. Oberneder; M. Stahler; N. Haseke; J. Beck; R. Hofman 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 311 KB

Recombinant interferon-alpha combined wi

Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma reduced toxicity without reduction of the response rate—a phase II study

✍ Sophie D. Fosså; Ragnhild Gunderson; Brit Moe 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 356 KB 👁 2 views